- Assess the impact of testing modalities for identifying patients with high-risk early-stage HR+/HER2- breast cancer in determining therapy selection and need for adjuvant therapies.
- Assess the efficacy and safety profiles of current and emerging agents used in adjuvant endocrine regimens for patients with high-risk early-stage HR+/HER2- breast cancer who are suitable for intensified adjuvant endocrine therapies.
- Integrate recent evidence on biomarkers and clinical trials into personalized adjuvant treatment management for patients with early-stage HR+/HER2- breast cancer.
- Evaluate the impact of new clinical evidence for novel treatment classes on HR+/HER2- breast cancer treatment paradigms and their implications for clinical practice and adverse effect.
Community Oncology Connections™: Navigating Early-Stage HR+/HER2- Breast Cancer – Clinical Developments and Innovative Treatments | Kansas
April 24, 2025
5:15 PM - 6:15 PM Central Time
Virtual Regional Meeting | Kansas
Overview:
This live, virtual symposium will bring together a nationally recognized expert and a local thought leader to discuss key advancements in the management of early-stage HR-positive, HER2-negative breast cancer. Through interactive discussions, participants will explore the role of testing modalities in identifying high-risk patients and guiding therapy selection, the efficacy and safety of current and emerging adjuvant endocrine therapies, and the integration of biomarker research into personalized treatment plans. The program will also address new treatment classes and best practices for managing adverse effects, providing practical insights to improve patient care.
Learning Objectives:
Upon completion of this activity, participants will be able to:
Target Audience:
This educational program is directed toward medical oncologists, APPs, nurses, pharmacists, researchers, and other healthcare professionals involved in the treatment of HR+/HER2- Breast Cancer.
Accreditation/Credit Designation:
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.
Acknowledgment of Educational Support
This activity is supported by educational grants from Lilly; Exact Sciences Corporation.
Have a question for the PER® team?
Email: info@gotoper.com
Health & Safety
Physicians’ Education Resource®, LLC’s (PER®’s) top priority is the safety and security of our attendees, faculty, exhibitors, staff, and operational personnel. As we develop the programming for this activity, PER® is working diligently to implement health and safety protocols based on the advice of health experts and the latest guidelines and local regulations to optimize health and safety conditions for attendees during the event. Please note that attendance at any public event increases the risk of contracting a communicable illness. Attendees assume all risk associated with attendance. Any attendees who feel ill, regardless of their symptoms, should not attend this event.
2 Commerce Drive Cranbury, NJ 08512
info@gotoper.com
Copyright ©2025
Physicians' Education Resource®, LLC.
All rights reserved
.png)